EcoR1 Capital’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

EcoR1 Capital’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-265,784	Closed	-$3.04M	–	42
2016 Q3	$3.04M	Buy	+265,784	New	+$3.09M	0.93%	27
2015 Q1	–	Sell	-157,038	Closed	-$3.42M	–	29
2014 Q4	$3.42M	Buy	+157,038	New	+$3.22M	1.73%	17

Other funds holding OMED

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EcoR1 Capital's OMED Position: Q4 2016 in Review

EcoR1 Capital sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2016, closing a stake of 265,784 shares — an estimated $3.04M sold.

EcoR1 Capital first reported a position in OMED in Q4 2014 and held it in 2 quarters. The position peaked at $3.42M in Q4 2014. 86 funds tracked by Wall St. Rank hold OMED as of Q4 2016.

EcoR1 Capital reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
EcoR1 Capital sold 265,784 OncoMed Pharmaceuticals, Inc. shares in Q4 2016, an estimated $3.04M.
EcoR1 Capital first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
EcoR1 Capital's OncoMed Pharmaceuticals, Inc. position peaked at $3.42M in Q4 2014.
86 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2016.

Based on EcoR1 Capital's 13F filing for Q4 2016, filed 14 Feb 2017.